UniProt Q9NWZ3 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Vandetanib | 86.9% | 13.1% | 95.74 | 0.723 |
| 2 | Gilteritinib | 86.3% | 13.7% | 88.97 | 0.506 |
| 3 | Pacritinib | 82.8% | 17.2% | 88.64 | 0.452 |
| 4 | Sunitinib | 80.8% | 19.2% | 91.73 | 0.524 |
| 5 | Brigatinib | 76.2% | 23.8% | 82.96 | 0.513 |
| 6 | Tepotinib | 72.7% | 27.3% | 99.75 | 0.727 |
| 7 | Bosutinib | 66.4% | 33.6% | 87.22 | 0.555 |
| 8 | Alectinib | 58.1% | 41.9% | 95.49 | 0.651 |
| 9 | Defactinib | 45.7% | 54.3% | 92.68 | 0.450 |
| 10 | Midostaurin | 45.5% | 54.5% | 78.64 | 0.500 |
| 11 | Gefitinib | 42.7% | 57.3% | 99.25 | 0.650 |
| 12 | Canertinib | 33.8% | 66.2% | 96.49 | 0.671 |
| 13 | Dacomitinib | 31.8% | 68.2% | 97.99 | 0.664 |
| 14 | Pexidartinib | 30.2% | 69.8% | 99.49 | 0.631 |
| 15 | Ponatinib | 25.9% | 74.1% | 78.23 | 0.534 |
| 16 | Tivozanib | 25.6% | 74.4% | 92.42 | 0.673 |
| 17 | Fostamatinib | 24.9% | 75.1% | 96.74 | 0.613 |
| 18 | Afatinib | 22.5% | 77.5% | 98.50 | 0.709 |
| 19 | Crizotinib | 22.3% | 77.7% | 91.39 | 0.581 |
| 20 | Lenvatinib | 19.7% | 80.3% | 97.74 | 0.726 |
Paralog block
IRAK1, IRAK4
EMT expression
- Mesenchymal log2(TPM+1): 3.31
- Epithelial log2(TPM+1): 2.97
- Fold change: 0.34
- Status: No significant change
High-confidence drugs
- Tepotinib — inh 72.7% · KISS 38.37
- Vandetanib — inh 86.9% · KISS 32.68
- Gilteritinib — inh 86.3% · KISS 18.49
Selectivity landscape vs inhibition on IRAK4
Each point is one of the 92 approved drugs; color = inhibition % on IRAK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…